Boston Scientific Net Acquisitions/Divestitures 2010-2025 | BSX
Boston Scientific annual/quarterly net acquisitions/divestitures history and growth rate from 2010 to 2025. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
- Boston Scientific net acquisitions/divestitures for the quarter ending March 31, 2025 were $-4.640B, a 156.21% increase year-over-year.
- Boston Scientific net acquisitions/divestitures for the twelve months ending March 31, 2025 were $-6.004B, a 42.21% increase year-over-year.
- Boston Scientific annual net acquisitions/divestitures for 2024 were $-4.64B, a 156.21% increase from 2023.
- Boston Scientific annual net acquisitions/divestitures for 2023 were $-1.811B, a 17.83% increase from 2022.
- Boston Scientific annual net acquisitions/divestitures for 2022 were $-1.537B, a 7.33% increase from 2021.
| Boston Scientific Annual Net Acquisitions/Divestitures (Millions of US $) |
|
|---|---|
| 2024 | $-4,640 |
| 2023 | $-1,811 |
| 2022 | $-1,537 |
| 2021 | $-1,432 |
| 2020 | $-134 |
| 2019 | $-4,292 |
| 2018 | $-1,448 |
| 2017 | $-560 |
| 2016 | $-408 |
| 2015 | $-1,734 |
| 2014 | $-500 |
| 2013 | $-244 |
| 2012 | $-356 |
| 2011 | $1,070 |
| 2010 | $-205 |
| 2009 | $-527 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $155.199B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||